Montag A & Associates Inc. Purchases 450 Shares of Danaher Co. (NYSE:DHR)

Montag A & Associates Inc. lifted its position in shares of Danaher Co. (NYSE:DHRFree Report) by 2.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,916 shares of the conglomerate’s stock after acquiring an additional 450 shares during the period. Montag A & Associates Inc.’s holdings in Danaher were worth $5,506,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in DHR. Silicon Valley Capital Partners purchased a new stake in Danaher in the first quarter worth approximately $29,000. Raleigh Capital Management Inc. boosted its holdings in Danaher by 68.9% in the first quarter. Raleigh Capital Management Inc. now owns 125 shares of the conglomerate’s stock worth $32,000 after purchasing an additional 51 shares during the last quarter. America First Investment Advisors LLC purchased a new stake in Danaher in the first quarter worth approximately $34,000. Beacon Capital Management LLC boosted its holdings in Danaher by 39.4% in the second quarter. Beacon Capital Management LLC now owns 216 shares of the conglomerate’s stock worth $52,000 after purchasing an additional 61 shares during the last quarter. Finally, Ogorek Anthony Joseph NY ADV purchased a new position in shares of Danaher during the 1st quarter worth $64,000. Institutional investors own 76.71% of the company’s stock.

Insider Transactions at Danaher

In related news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of Danaher stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $250.54, for a total transaction of $147,818.60. Following the completion of the transaction, the senior vice president now directly owns 6,939 shares of the company’s stock, valued at approximately $1,738,497.06. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 11.10% of the company’s stock.

Danaher Price Performance

NYSE DHR traded up $1.48 on Friday, reaching $197.00. The company had a trading volume of 2,110,028 shares, compared to its average volume of 3,666,895. The company has a quick ratio of 1.94, a current ratio of 2.26 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $145.57 billion, a PE ratio of 24.84, a price-to-earnings-growth ratio of 1.96 and a beta of 0.81. The firm’s 50 day moving average price is $223.18 and its 200 day moving average price is $235.92. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.54.

Danaher (NYSE:DHRGet Free Report) last announced its quarterly earnings results on Tuesday, October 24th. The conglomerate reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.19. Danaher had a net margin of 20.01% and a return on equity of 13.71%. The company had revenue of $6.87 billion for the quarter, compared to the consensus estimate of $6.60 billion. During the same period in the previous year, the firm posted $2.56 EPS. Danaher’s revenue for the quarter was down 10.3% compared to the same quarter last year. As a group, equities analysts predict that Danaher Co. will post 8.36 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Thursday, October 12th were issued a $0.27 dividend. The ex-dividend date of this dividend was Wednesday, October 11th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.55%. Danaher’s dividend payout ratio (DPR) is presently 13.62%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DHR shares. The Goldman Sachs Group dropped their price target on shares of Danaher from $250.00 to $215.00 and set a “buy” rating on the stock in a research note on Thursday, October 26th. Royal Bank of Canada dropped their price target on shares of Danaher from $246.00 to $239.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 25th. Wells Fargo & Company dropped their price target on shares of Danaher from $285.00 to $247.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 3rd. Barclays dropped their price target on shares of Danaher from $290.00 to $215.00 and set an “overweight” rating on the stock in a research note on Thursday, October 26th. Finally, Citigroup dropped their price target on shares of Danaher from $265.92 to $240.00 and set a “buy” rating on the stock in a research note on Wednesday, October 25th. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $257.73.

Read Our Latest Report on Danaher

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.

Recommended Stories

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.